TG THERAPEUTICS, INC. (TGTX) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $745.39M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD (m); Notes Payable, Fair Value DisclosureUSD $1.30M; Convertible Notes Payable, CurrentUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $745.14M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $4.90M; Notes Payable, Fair Value DisclosureUSD $777.00K; Convertible Notes Payable, CurrentUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $245.65M; Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD (m); Notes Payable, Fair Value DisclosureUSD $689.00K; Convertible Notes Payable, CurrentUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, NetUSD $4.40M; Notes Payable, Fair Value DisclosureUSD (m); Convertible Notes Payable, CurrentUSD (m).
TG THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Notes Payable, Fair Value Disclosure USD | Convertible Notes Payable, Current USD | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Convertible Notes Payable USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two and Three USD | Long-Term Debt, Maturity, Year Four and Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Interest Rate During Period pure | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument Repaid Principal USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $745.39M | (m) | $1.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $745.14M | $4.90M | $777.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $245.65M | (m) | $689.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $4.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $245.34M | (m) | $824.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $245.04M | (m) | $810.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $244.73M | (m) | $874.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $244.43M | (m) | $661.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $244.16M | (m) | $508.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $0.00 |
| 2024-06-30 | $102.54M | (m) | $381.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $106.37M | $95.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $0.00 |
| 2024-03-31 | $101.33M | (m) | $322.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $105.80M | $95.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $100.12M | (m) | $357.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $0.00 |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $105.23M | $95.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.40M | $0.00 | $100.40M | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $0.00 |
| 2023-09-30 | $98.91M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | $98.91M | (m) | (m) | (m) | (m) | $104.66M | $95.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $97.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $97.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.95% | (m) | (m) | (m) | (m) |
| 2023-03-31 | $96.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $96.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $0.00 |
| 2022-12-31 | $71.14M | (m) | $243.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $76.67M | $70.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $71.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $0.00 |
| 2022-09-30 | $71.14M | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | $71.14M | (m) | (m) | (m) | (m) | $76.67M | $70.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $68.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $68.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $67.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $67.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $66.79M | (m) | $360.00K | (m) | (m) | $975.00K | (m) | (m) | $67.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $623.00K | (m) | (m) | $16.00M | (m) | (m) | $30.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $717.00K | (m) | (m) | $23.16M | (m) | (m) | $30.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $880.00K | (m) | (m) | $30.13M | (m) | (m) | $30.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.72M | (m) | $938.00K | (m) | (m) | $22.18M | (m) | (m) | $29.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | $938.00K | (m) | (m) | $938.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $15.07M | (m) | $477.00K | (m) | $477.00K | $14.59M | (m) | $477.00K | $29.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $22.23M | (m) | $343.00K | (m) | $343.00K | $7.20M | (m) | $343.00K | $29.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $29.20M | (m) | $171.00K | (m) | $171.00K | (m) | (m) | $171.00K | $29.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $28.97M | (m) | $190.00K | (m) | $190.00K | $0.00 | (m) | $190.00K | $28.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $28.74M | (m) | $95.00K | (m) | $95.00K | $0.00 | (m) | $95.00K | $28.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $28.51M | (m) | $145.00K | (m) | $145.00K | $0.00 | (m) | $145.00K | $28.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $28.29M | (m) | $133.00K | (m) | $133.00K | $0.00 | (m) | $133.00K | $28.29M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | (m) | $67.00K | (m) | $67.00K | (m) | (m) | $67.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $91.00K | (m) | $91.00K | (m) | (m) | $91.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $210.00K | (m) | $210.00K | (m) | (m) | $210.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $224.00K | (m) | $224.00K | (m) | (m) | $224.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $128.00K | (m) | $128.00K | (m) | (m) | $128.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $182.16K | (m) | $182.16K | (m) | (m) | $182.16K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $152.57K | (m) | $152.57K | (m) | (m) | $152.57K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $174.66K | (m) | $174.66K | (m) | (m) | $174.66K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $68.88K | (m) | $68.88K | (m) | (m) | $68.88K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $117.13K | (m) | $117.13K | (m) | (m) | $117.13K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $90.56K | (m) | $90.56K | (m) | (m) | $90.56K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 5.00% | (m) | (m) |
| 2016-03-31 | (m) | (m) | $152.92K | (m) | $152.92K | (m) | (m) | $152.92K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.12K | (m) |
| 2015-12-31 | (m) | (m) | $211.55K | (m) | $211.55K | (m) | (m) | $211.55K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 5.00% | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.12K | (m) |
| 2015-09-30 | (m) | (m) | $181.67K | (m) | $181.67K | (m) | (m) | $181.67K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $295.36K | (m) | $295.36K | (m) | (m) | $295.36K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · 5.00% | (m) | (m) |
| 2015-03-31 | (m) | (m) | $272.21K | (m) | $272.21K | (m) | (m) | $272.21K | (m) | (m) | (m) | (m) | (m) | $19.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 5.00% | (m) | (m) |
| 2014-12-31 | (m) | (m) | $275.19K | (m) | $275.19K | (m) | (m) | $275.19K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $19.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $183.14K | (m) | $183.14K | (m) | (m) | $183.14K | (m) | (m) | (m) | (m) | (m) | $19.31M | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $159.21K | (m) | $159.21K | (m) | (m) | $159.21K | (m) | (m) | (m) | (m) | (m) | $19.07M | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $115.55K | (m) | $0.00 | (m) | (m) | $115.55K | (m) | (m) | (m) | (m) | (m) | $18.84M | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $64.53K | (m) | $677.78K | (m) | (m) | $742.31K | (m) | (m) | (m) | (m) | (m) | $18.61M | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $2.27M | (m) | $677.78K | (m) | (m) | $2.95M | (m) | (m) | (m) | (m) | (m) | $18.39M | (m) | (m) | 5.00% | 5.00% | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $2.36M | (m) | $677.78K | (m) | (m) | $3.04M | (m) | (m) | (m) | (m) | (m) | $18.17M | (m) | (m) | 5.00% | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $2.42M | (m) | $677.78K | (m) | (m) | $3.10M | (m) | (m) | (m) | (m) | (m) | $17.94M | (m) | $3.29M | 5.00% | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $2.48M | (m) | $677.78K | (m) | (m) | $3.16M | (m) | (m) | (m) | (m) | (m) | $17.73M | (m) | (m) | (m) | 5.00% | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.29M | 5.00% | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | $0.00 | $677.78K | (m) | $4.38M | $5.06M | (m) | (m) | (m) | (m) | (m) | $17.52M | (m) | $4.38M | 5.00% | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | $0.00 | $677.78K | (m) | $4.40M | $5.07M | (m) | (m) | (m) | (m) | (m) | $17.30M | (m) | $4.66M | 5.00% | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | $677.78K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 5.00% | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.29M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $3.29M | (m) | $877.78K | (m) | (m) | $4.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $4.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | $761.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | $775.29K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | $2.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1.12K | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |